GlassScriptPhysician profile
Millicent M Mutisya
NPI 1285308528
$1,265.66
in general payments reported to CMS, 2019-2025
31 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.20 · 2022: $120 · 2023: $320 · 2024: $425 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.15 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $144.97 | 2021-2024 | Reblozyl, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $131.60 | 2021-2024 | Erleada, Carvykti, Rybrevant |
| Mirati Therapeutics, INC. | $115.09 | 2023 | Krazati |
| Seagen INC. | $84.99 | 2023 | |
| Tersera Therapeutics LLC | $50.59 | 2022-2023 | Zoladex |
| Array Biopharma INC | $49.83 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Incyte Corporation | $49.26 | 2024-2025 | Jakafi, Jakafi |
| Genzyme Corporation | $47.90 | 2024-2025 | |
| Lilly USA, LLC | $46.11 | 2025 | Jaypirca, Verzenio |
| Beigene USA, INC. | $41.35 | 2023 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $38.30 | 2024 | Libtayo |
| Daiichi Sankyo INC. | $34.35 | 2022-2025 | Injectafer |
| Pharmacyclics LLC, An Abbvie Company | $33.98 | 2023 | Epkinly |
| Syndax Pharmaceuticals, INC. | $33.70 | 2025 | |
| Pharmaessentia USA Corporation | $31.82 | 2024 | Besremi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $27.46 | 2025 | Udenyca |
| Takeda Pharmaceuticals U.S.A., INC. | $26.23 | 2025 | Iclusig |
| Astrazeneca Pharmaceuticals LP | $26.22 | 2025 | Lynparza |
| Exelixis INC. | $25.84 | 2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $25.53 | 2024 | |
| Novartis Pharmaceuticals Corporation | $21.86 | 2025 | |
| Myovant Sciences INC. | $21.69 | 2021 | |
| Taiho Oncology, INC. | $21.39 | 2024 | |
| Adaptive Biotechnologies Corporation | $20.22 | 2022 | |
| Foundation Medicine, INC. | $18.48 | 2022 | |
| Sobi, INC | $18.16 | 2024 | |
| Deciphera Pharmaceuticals INC. | $18.16 | 2025 | Romvimza, Qinlock |
| Pfizer INC. | $16.04 | 2024 | |
| Puma Biotechnology, INC. | $15.91 | 2025 | |
| Amgen INC. | $14.99 | 2022 | |
| Abbvie INC. | $13.64 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millicent Mutisya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.